ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0171

Cardiac Involvement in Idiopathic Inflammatory Myopathies: When Should We Look for It?
Abstract Number: 2169

Cardiac Rhythm and Conduction Abnormalities in Systemic Sclerosis-meta-analysis
Abstract Number: 1846

Cardiac Sarcoidosis: An Underdiagnosed, Life-threatening yet Treatable Disease
Abstract Number: 0722

Cardiovascular and Oncologic Outocomes of Anti-TNF Alfa and JAK Inhibitors in Patients with Rheumatoid and Psoriatic Arthritis. Real World Data and Insights of BIOBADASAR 3.0 Registry
Abstract Number: 0888

Cardiovascular and Thromboembolic Events in Rheumatoid Arthritis Patients Before and After Initiation of a First Advanced Therapy. Data from the University of Sherbrooke Registry of Advanced Therapies (USRAT)
Abstract Number: 0445

Cardiovascular Burden in Patients with ANCA-Associated and Non-ANCA Associated Vasculitis
Abstract Number: 1016

Cardiovascular Disease Proteome Profile Is Related to an Abnormal Methylome Pattern in Spondyloarthritis: Potential Biomarkers of Subclinical Atherosclerosis
Abstract Number: 1466

Cardiovascular Risk Assessment in Patients with Systemic Lupus Erythematosus: Comparison Between QRISK and aGAPSS Scores
Abstract Number: 2001

Cardiovascular Risk Factors and Therapeutic Outcome in Rheumatoid Arthritis – Real World Data
Abstract Number: 1710

CCL2 Drives Interferon-enhanced Monocytosis in UV-mediated Skin Injury in Murine Lupus
Abstract Number: 0766

CCP+ Immune Checkpoint Inhibitor Arthritis Patients Have Less ACPA Epitope Expansion Than CCP+ Rheumatoid Arthritis Patients
Abstract Number: 0008

CD11c+ T-Bet+ B Cells Traffic to Human Bone Marrow
Abstract Number: 0624

CD20+ T Cells in the Synovial Fluid of Patients with Rheumatoid Arthritis Suggest a Role for Trogocytosis in Disease Pathogenesis and Activity
Abstract Number: 1124

CD4+ Cytotoxic T Lymphocytes (CTL) Are Present in Sjögren’s Disease Minor Salivary Glands and Associate with Markers of Epithelial Cell Damage near Infiltrates
Abstract Number: 1572

CD40, BLK and BANK1 in the Pathogenesis of Immunoglobulin-A Vasculitis

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].